Short answer
BridgeBio Pharma, Inc. (BBIO) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $353M (up 192.6% year over year) with net income of −$57M.
Q3 2026 key financials · XBRL
- Revenue
- $353M
- +192.6% YoY · +44.9% QoQ
- Net income
- −$57M
- +69.0% YoY · +62.7% QoQ
- Operating margin
- -3.3%
- EPS (diluted)
- −$0.42
- +55.8% YoY · +46.2% QoQ
Source: XBRL data from the BridgeBio Pharma, Inc. (BBIO) Q3 2026 10-Q on SEC EDGAR. USD.
BridgeBio Pharma, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $353.2M, up $232.5M YoY, driven by Attruby product revenue $253.3M vs $108.1M
- Operating margin negative 3.3% vs negative 120.3% YoY, based on operating loss $11.6M vs $145.2M
- Best line: Attruby revenue up $145.3M; worst line: license and services revenue up $71.0M, boosted by a $75.0M Bayer milestone
- Cash, equivalents and securities $1.5B vs $587.5M; operating cash outflow $312.6M for nine months
- Near-term losses expected for several years; liquidity projected for at least 12 months, with headwinds from commercialization, inflation and supply chain issues
Risk Factors
- New regulatory risk: CMS finalized GLOBE on October 2, 2026, requiring internationally benchmarked Medicare Part B rebates beginning January 1, 2027
- Most material update: FDA scrutiny of promotional practices, including an untitled letter concerning Attruby’s DTC broadcast advertisement
- Compliance exposure: Medicaid, 340B and VA pricing errors could trigger refunds, civil penalties, or program termination
- Commercial risk: Attruby faces competition as it is not the first ATTR-CM treatment on the market
- Supply risk: Attruby and Beyonttra rely on one primary drug-product supplier, despite a secondary supplier agreement
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other BridgeBio Pharma, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.